Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)

Takeda ; class='js-l-obf link link--blue'

Related Keywords

Japan ,United States ,Clin Gastroenterol Hepatol ,Vijay Yajnik ,Takeda Pharmaceutical Company Limited ,Exchange Commission ,Drug Administration ,New Drug Application ,Eosinophilic Esophagitis ,Annual Report ,Markets ,